GLP-1 receptor agonists and lymphedema: from weight loss to potential direct modulation of lymphatic function

Obesity and lymphedema are linked through increased interstitial fluid load, impaired collecting-vessel pumping, inflammation, and progressive fibro-adipose remodeling. This bidirectional relationship makes glucagon-like peptide-1 receptor agonists (GLP-1RAs) relevant through two potentially distinct pathways. First, substantial weight loss may unload a compromised lymphatic system, improve mobility, and reduce adipose-driven inflammation. Second, GLP-1 signaling may directly influence lymphatic vessel function. Case reports and a retrospective cohort have described reduced limb volume, improved symptoms or imaging findings, and a lower incidence of breast cancer-related lymphedema among GLP-1RA users. Experimental work has identified GLP-1 receptors in lymphatic endothelial cells and shown that pharmacological activation with semaglutide increases the pumping capacity of isolated collecting lymphatic vessels. These findings support a potential direct lymphatic effect but do not establish clinical efficacy in human lymphedema. Improvement during treatment may instead reflect reduced fat mass, greater mobility, or changes in conventional care. Future studies should distinguish weight-loss-dependent unloading from weight-loss-independent effects by combining standardized clinical outcomes, functional imaging, body-composition measurements, and, where feasible, weight-matched comparison groups. The available evidence therefore supports prospective investigation rather than clinical adoption. Trials should assess early vascular responses before major weight loss, longer-term changes in tissue composition and inflammation, and durability after treatment withdrawal, while maintaining standardized compression, exercise, skin care, and other components of established lymphedema management throughout. Until such evidence is available, GLP-1RAs should be prescribed for established metabolic indications rather than lymphedema itself, and any lymphatic benefit should be regarded as a promising clinical signal rather than a treatment claim.